Rimota-Gd: Paramagnetic Probe for In Vivo MRI Studies of the Cannabinoid 1 Receptor Distribution in the Mouse Brain DOI

Ouyang Qi,

Fei Zhao, Jingjing Ye

et al.

ACS Chemical Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 14, 2024

The cannabinoid 1 receptor (CB1) is highly expressed in the central nervous system, where its physiological functions include regulation of energy balance, pain, and addiction. Herein, we develop validate a technique to use magnetic resonance imaging (MRI) investigate distribution CB1 across mouse brains with high spatial resolution, expanding previously described vitro studies vivo positron emission tomography (PET). To support MRI investigations, developed ligand that specific for neuroimaging CB1. By chemically conjugating antagonist rimonabant acid gadolinium chelator, obtained paramagnetic probe Rimota-Gd. specificity binding relaxation enhancement by permit MRI-based localization We used Rimota-Gd brain compared results an investigation using PET radioligand [

Language: Английский

Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives DOI Creative Commons
Virendra Kumar Yadav, Seshathiri Dhanasekaran, Nisha Choudhary

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 22, 2025

Parkinson’s disease is a progressive neurodegenerative that destroys substantia nigra dopaminergic neurons, causing tremors, bradykinesia, rigidity, and postural instability. Current treatment approaches primarily focus on symptom management, employing pharmacological, non-pharmacological, surgical methods. However, these treatments often result in fluctuating symptoms, side effects, progression. Here, the authors have reviewed emerging field of nanomedicine as promising path for treatment, emphasizing its potential to overcome limitations traditional therapies. Nanomedicine utilizes nanoparticles targeted drug delivery, leveraging their small size high surface area volume ratio cross blood-brain barrier deliver therapeutic agents directly affected brain regions. Various nanoparticles, including lipid-based, polymeric, metallic, carbon-based, shown treatment. Additionally, nanocarrier systems like liposomes, nanogels, dendrimers, solid lipid offer controlled sustained release agents, enhancing bioavailability reducing effects. This review provides insights into pathophysiology disease, highlighting mechanisms neurodegeneration, role alpha-synuclein, disruption pathways. It further discusses application gene therapy conjunction with interventions.

Language: Английский

Citations

2
Nanodiamond-mediated delivery of microRNA-7 for the neuroprotection of dopaminergic neurons DOI Creative Commons
Yuping Han, Yue Yao, Xinyi Wen

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 12

Published: Jan. 8, 2025

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the gradual loss of dopaminergic neurons in substantia nigra and accumulation α-synuclein aggregates known as Lewy bodies. MicroRNA-7 (miR-7) targets gene SNCA, which encodes α-synuclein, reducing its expression alleviating neuronal damage PD. Regulating post-transcriptional levels through miR-7 effectively inhibits production. Herein, we use nanodiamonds carriers to deliver (N-7), can protect neurons. Dopaminergic efficiently take up N-7 express miR-7. reduces oxidative stress restores dopamine effectively. These findings suggest that nanocomposites have significant potential treating

Language: Английский

Citations

1
Oxidative Stress and Mitochondrial Impairment: Key Drivers in Neurodegenerative Disorders DOI

Pei Wen,

Zhixin Sun,

Fengting Gou

et al.

Ageing Research Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 102667 - 102667

Published: Jan. 1, 2025

Language: Английский

Citations

0
Regulator of oxidative balance: Research progress of nanozymes in ROS-related diseases DOI
Xiang Wang, Zidong Wang, Siyuan Hu

et al.

Materials Today Chemistry, Journal Year: 2025, Volume and Issue: 44, P. 102540 - 102540

Published: Jan. 22, 2025

Language: Английский

Citations

0
Nanozymes in biomedicine: Unraveling trends, research foci, and future trajectories via bibliometric insights (from 2007 to 2024) DOI
Siyang Cao,

Yingchen Pang,

Yihao Wei

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 142798 - 142798

Published: April 1, 2025

Language: Английский

Citations

0
Effects and mechanisms of long-acting glucagon-like peptide-1 receptor agonist semaglutide on microglia phenotypic transformation and neuroinflammation after cerebral ischemia/reperfusion in rats DOI Creative Commons

Rulin Mi,

Hui-Feng Cheng,

Rui Chen

et al.

Brain Circulation, Journal Year: 2024, Volume and Issue: 10(4), P. 354 - 365

Published: Oct. 1, 2024

The optimal method for addressing cerebral ischemic stroke involves promptly restoring blood supply. However, ischemia-reperfusion injury (CIRI) is an unavoidable consequence of this event. Neuroinflammation deemed the primary mechanism CIRI, with various activation phenotypes microglia playing a pivotal role. Research has demonstrated that long-lasting agonists glucagon-like peptide-1 receptor can suppress neuroinflammation and microglial activation. A transient middle artery occlusion (tMCAO) rat model was established to investigate effects semaglutide. Neurological impairments were evaluated utilizing modified neurological severity score on days 1, 3, 7 postinterventions. Brains stained 2,3,5-Triphenyltetrazolium Chloride determine infarct volume. To assess expression neuroinflammatory biomarkers, we utilized immunohistochemistry immunoblotting. study semaglutide in tMCAO could decrease deficit scores reduce size infarcts. In addition, observed low levels cluster differentiation 68 (CD68, indicator M1 activation) tumor necrosis factor alpha (a pro-inflammatory mediator). Moreover, results indicated rise CD206 (an M2 transforming growth beta anti-inflammatory mediator), while simultaneously reducing P65 nuclear kappa-light-chain-enhancer activated B cells (NF-κB) signaling cascade. CIRI model, exhibits notable neuroprotective rats, through regulation phenotype transformation inhibition NF-κB

Language: Английский

Citations

2
HDAC6 inhibitor-loaded brain-targeted nanocarrier-mediated neuroprotection in methamphetamine-driven Parkinson’s disease DOI Creative Commons
Khang‐Yen Pham,

Shristi Khanal,

Ganesh Bohara

et al.

Redox Biology, Journal Year: 2024, Volume and Issue: 79, P. 103457 - 103457

Published: Dec. 5, 2024

The dynamic equilibrium between acetylation and deacetylation is vital for cellular homeostasis. Parkinson's disease (PD), a neurodegenerative disorder marked by α-synuclein (α-syn) accumulation dopaminergic neuron loss in the substantia nigra, associated with disruption of this balance. Therefore, correcting imbalance histone deacetylase (HDAC) inhibitors represents promising treatment strategy PD. CAY10603 (CAY) potent selective HDAC6 inhibitor. However, because its poor water solubility short biological half-life, it faces clinical limitations. Herein, we engineered lactoferrin-decorated CAY-loaded poly(lactic-co-glycolic acid) nanoparticles (denoted as PLGA@CAY@Lf NPs) to effectively counter methamphetamine (Meth)-induced NPs showed enhanced blood-brain barrier crossing significant brain accumulation. Notably, CAY released from restored disrupted balance PD, resulting neuroprotection reversing mitochondrial dysfunction, suppressing reactive oxygen species, inhibiting α-syn Additionally, normalized dopamine tyrosine hydroxylase levels, reduced neuroinflammation, improved behavioral impairments. These findings underscore potential treating Meth-induced PD suggest that an innovative HDAC6-inhibitor-based can be used treat

Language: Английский

Citations

1
Intragland Expression of the Shh Gene Alleviates Irradiation-Induced Salivary Gland Injury through Microvessel Protection and the Regulation of Oxidative Stress DOI Creative Commons

Meijun Hu,

Hu L, Tao Yang

et al.

Antioxidants, Journal Year: 2024, Volume and Issue: 13(8), P. 904 - 904

Published: July 26, 2024

Radiation-induced salivary gland injury (RISGI) is a common complication of radiotherapy in patients with head and neck cancer. Intragland expression the Sonic Hedgehog (Shh) gene may partially rescue irradiation (IR)-induced hyposalivation by preserving stem/progenitor cells parasympathetic innervation, maintaining resident macrophages, microvascular density. Previous studies have revealed that Ad-Rat Shh transduction through glands miniature pigs can ameliorate oxidative stress-induced dysfunction after radiotherapy. Changes parotid flow rate were analyzed, tissue was collected at 5 20 weeks IR. pathway vascular function-related markers (vascular endothelial growth factor (VEGF) CD31) stress-related detected via immunohistochemistry, immunofluorescence, Western blotting. A stable Shh-overexpressing cell line generated from human umbilical vein (HUVECs) exposed to 10 Gy X-ray irradiation, which proliferation, senescence, apoptosis, function evaluated. We found intragland efficiently alleviated IR-induced pig model. Our results indicate antioxidative stress microvascular-protective effects Hh are regulated nuclear factor-erythroid 2-related 2 (Nrf2).

Language: Английский

Citations

0
Rimota-Gd: Paramagnetic Probe for In Vivo MRI Studies of the Cannabinoid 1 Receptor Distribution in the Mouse Brain DOI

Ouyang Qi,

Fei Zhao, Jingjing Ye

et al.

ACS Chemical Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 14, 2024

The cannabinoid 1 receptor (CB1) is highly expressed in the central nervous system, where its physiological functions include regulation of energy balance, pain, and addiction. Herein, we develop validate a technique to use magnetic resonance imaging (MRI) investigate distribution CB1 across mouse brains with high spatial resolution, expanding previously described vitro studies vivo positron emission tomography (PET). To support MRI investigations, developed ligand that specific for neuroimaging CB1. By chemically conjugating antagonist rimonabant acid gadolinium chelator, obtained paramagnetic probe Rimota-Gd. specificity binding relaxation enhancement by permit MRI-based localization We used Rimota-Gd brain compared results an investigation using PET radioligand [

Language: Английский

Citations

0